Abbott Laboratories (NYSE:ABT) Updates FY 2025 Earnings Guidance

Abbott Laboratories (NYSE:ABT - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 5.050-5.250 for the period, compared to the consensus earnings per share estimate of 5.150. The company issued revenue guidance of -. Abbott Laboratories also updated its Q2 2025 guidance to 1.230-1.270 EPS.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. StockNews.com cut Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 12th. Royal Bank of Canada upped their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Thursday. Jefferies Financial Group raised their target price on shares of Abbott Laboratories from $135.00 to $137.00 and gave the stock a "hold" rating in a report on Thursday. Bank of America upped their price target on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Finally, Argus upgraded Abbott Laboratories to a "strong-buy" rating in a research note on Tuesday, January 28th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $142.59.

Abbott Laboratories Price Performance

Shares of ABT stock traded down $1.80 during trading hours on Monday, hitting $129.18. The stock had a trading volume of 1,758,612 shares, compared to its average volume of 6,010,206. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The stock's 50-day moving average price is $130.62 and its two-hundred day moving average price is $121.96. The stock has a market capitalization of $224.04 billion, a price-to-earnings ratio of 16.89, a PEG ratio of 2.52 and a beta of 0.80.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.02. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 30.61%.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the sale, the executive vice president now directly owns 74,381 shares of the company's stock, valued at $10,277,222.77. The trade was a 1.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the transaction, the executive vice president now directly owns 71,928 shares in the company, valued at $9,625,404.96. The trade was a 55.90 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 116,449 shares of company stock valued at $15,463,316. Insiders own 0.46% of the company's stock.

Institutional Trading of Abbott Laboratories

A hedge fund recently raised its stake in Abbott Laboratories stock. Brighton Jones LLC lifted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 51,719 shares of the healthcare product maker's stock after purchasing an additional 4,755 shares during the quarter. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 as of its most recent SEC filing. 75.18% of the stock is currently owned by institutional investors and hedge funds.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.